View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
May 22, 2011

GTx Unveils Positive Results from Ostarine Trial

GTx has announced positive results from a phase IIb clinical trial evaluating Ostarine, a selective androgen receptor modulator that could be used to treat muscle wasting in cancer patients. The trial involved 159 patients and showed that the receptor modulator improved the physical fun

By cms admin

GTx has announced positive results from a phase IIb clinical trial evaluating Ostarine, a selective androgen receptor modulator that could be used to treat muscle wasting in cancer patients.

The trial involved 159 patients and showed that the receptor modulator improved the physical function and overcame the negative prognostic effects of severe weight loss on overall survival in patients with non-small cell lung cancer.

GTx CEO Mitchell S Steiner said that non-small cell lung cancer patients with severe muscle loss have poorer treatment outcomes and shorter overall survival.

“This wasting and associated decline in function may have detrimental consequences early in the course of a patient’s malignancy, underscoring the importance of treating this condition at an early stage,” said Steiner.

In the third quarter of 2011, GTx is expected to initiate two pivotal phase III clinical trials evaluating Ostarine for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer.

Muscle loss is an independent predictor of performance status, cancer treatment tolerability, progression-free survival and overall survival.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Get important industry news and analysis sent to your inbox
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Hospital Management